Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy
暂无分享,去创建一个
C. Pozzilli | G. Comi | A. Lugaresi | A. Uccelli | G. Mancardi | A. Laroni | V. Brescia Morra | L. Guidi | D. Brogi | R. Turrini | Debora Raimondi | Davide Brogi
[1] L. Kappos,et al. Long-term effects of fingolimod in multiple sclerosis , 2015, Neurology.
[2] S. Amor,et al. The sphingosine 1‐phosphate receptor agonist FTY720 is neuroprotective after cuprizone‐induced CNS demyelination , 2015, British journal of pharmacology.
[3] J. Newcombe,et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide , 2014, Annals of neurology.
[4] M. Freedman,et al. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. , 2014, Multiple sclerosis and related disorders.
[5] Jeffrey A. Cohen,et al. Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. , 2014, Multiple sclerosis and related disorders.
[6] Ludwig Kappos,et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.
[7] C. Pozzilli,et al. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial , 2014, BMC Neurology.
[8] L. Kappos,et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy , 2014, Multiple sclerosis.
[9] L. Kappos,et al. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study , 2013, Journal of Neurology.
[10] R. Jager,et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. , 2013, Ophthalmology.
[11] Jeffrey A. Cohen,et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS , 2013, Journal of Neurology.
[12] Volker Brinkmann,et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.
[13] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[14] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[15] H. Rosen,et al. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules , 2009, Nature Reviews Drug Discovery.
[16] L. Kappos,et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis , 2008, Neurology.
[17] V. Brinkmann. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.
[18] Ludwig Kappos,et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[19] G. Francis,et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis , 2010, Nature Reviews Drug Discovery.